$XBI $148.22 +1% 📈
Want to access our searchable database of over 900 catalysts and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$IBRX +1% Presents interim safety data from ph 1 study of AAV hAd5 T-cell covid vaccine. The independant review committee recommended the study continue with no trial modification. source
$MRNA +5% First patient dosed in ph 1 study of mRNA-1283 in next-gen covid vaccine. source
Pipeline Updates
$BLUE +3% Presents updated long term data for eli-cel in CALD at EMBT 2021. source
$AUPH +4% Positive cost-effectiveness assessment by ICER on LUPKYNIS for lupus nephritis (LN). source
$GILD +5% & $MRK +2% Co-develop and commercialize combo treatment of lenacapavir and islatravir for HIV. source
$ACRS -5% Completes enrollment in ph 2a study of ATI-1777 for atopic dermatitis. Data expected mid-2021. source
$CORT +1% Enrolled first patient in ph 1b trial of relacorilant + pembro (Keytruda) in adrenal cancer with cortisol excess. source
$GLTO -6% Interim update from DSMB of ph 2b GALACTIC-1 study. 3mg arm to continue, other treatment arms discontinued. source
$RUBY +80% Announces initial data from ph 1/2 trial of RTX-240 in advanced solid tumors. source
$EQ +5% Announces data from EQUATE study in acute graft-versus-host disease at EBMT 2021. source
$MGTA -1% Presents final ph 1 results of MGTA-145 in stem cell mobilization program at EBMT 2021. source
$URGN -1% Sponsored research agreement with Johns Hopkins to study RTGel in Glioblastoma (GBM). Nonclinical research expected to begin 2Q 2021. source
$SRRK +2% Will present TOPAZ interim data in spinal muscular atrophy at MDA 2021 on 3/18. source
$SLDB -17% Reported interim data from ongoing IGNITE ph 1/2 trial of SGT-001 in Duchenne muscular dystrophy. source
Financial Updates
$AVEO -2% Regains rights to AV-203 ex-US. source
$BHVN +0% Offering. source
$RUBY +80% Offering. source
Comments